Clinical Update
June 15, 2025
Dr. Sarah Chen, Chief Scientific Officer
Nanotrol™ Formulation Achieves 10x Enhanced Bioavailability in Preclinical Studies
Breakthrough results from our latest preclinical studies demonstrate that our proprietary Nanotrol™ enhanced salsalate formulation achieves unprecedented 10x improvement in bioavailability compared to standard formulations. This milestone represents a critical advancement in our AI-driven CRS management platform, positioning us for accelerated clinical development and regulatory approval pathways.
Read Full Article
Funding
June 10, 2025
Nanotrol™ Therapeutics Announces $2M Seed Funding Round
Leading biotech investors recognize the transformative potential of our AI-driven CRS management platform. The funding will accelerate preclinical development and advance our regulatory pathway toward Phase I clinical trials.
Read More
Technology
June 5, 2025
AI Algorithm Validation Completed for Real-Time Biomarker Integration
Our multi-agent optimization system successfully demonstrates 85% accuracy in predicting severe CRS events, enabling proactive intervention strategies that could revolutionize CAR-T therapy safety protocols.
Read More
Partnerships
May 28, 2025
Strategic Partnership with Leading Cancer Research Institute
Collaboration agreement established to accelerate clinical validation of our CRS management platform across multiple CAR-T therapy protocols, expanding our research capabilities and regulatory pathway.
Read More
Awards
May 22, 2025
Nanotrol™ Receives Innovation Award at BioTech Summit 2025
Recognition for breakthrough AI-driven therapeutic optimization technology at the premier biotechnology conference, highlighting our unique approach to personalized CRS management.
Read More